Join our daily newsletter At The Bell to receive exclusive market insights
- Biotechnology company Immutep (IMM) has been advised by GSK that its phase two clinical trial on ulcerative colitis has been discontinued
- IMM had been testing an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, on patients with the bowel disease
- However, GSK has decided to stop the trial after conducting an assessment on the clinical data during a planned study break
- The licencing partner now wants to assess the efficacy and safety data of GSK2831781, as well evaluate the biology to determine what happens next
- Despite the trial being discontinued, Immutep’s collaboration with GSK continues as does its three other trials for other treatments
- Shares in IMM are trading down 8.14 per cent at 39.5 cents each
Biotechnology company Immutep (IMM) has been advised that its phase two clinical trial on ulcerative colitis has been discontinued.
Immutep teamed up with global healthcare company GSK to test an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, on patients with the bowel disease.
But, the trial has now been stopped by GSK on the basis that the business conducted an assessment on the clinical data during a planned study break.
The licencing partner said it needs to assess the efficacy and safety data of GSK2831781, as well as evaluate the biology to determine next steps for the program.
Despite the trial being discontinued, GSK’s and Immutep’s ongoing collaboration agreement remains in place for this treatment.
Under the terms of the deal, IMM is eligible to receive up to £54 million (around $95.5 million) in remaining milestone payments and additional royalties if GSK2831781 is commercialised.
Additionally, Immutep’s three other product candidates will continue being developed as planned — as the trial end has no financial impact on Immutep.
Following today’s announcement though, the company’s share price has dipped 8.14 per cent in the red at 39.5 cents each at 11:50 am AEDT.
